Alpha Tau Medical LTD. (DRTS) — SEC Filings
Latest SEC filings for Alpha Tau Medical LTD.. Recent 6-K filing on Apr 23, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.
View Alpha Tau Medical LTD. on SEC EDGAR
Overview
Alpha Tau Medical LTD. (DRTS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 23, 2026: Alpha Tau Medical Ltd. announced on April 23, 2026, positive results from two clinical trials. The ACAPELLA trial showed a 90% response rate in patients with unresectable, locally advanced, or metastatic cutaneous T-cell lymphoma (CTCL). The IMPACT trial demonstrated a 75% objective response rate in
Sentiment Summary
Across 2 filings, the sentiment breakdown is: 1 bullish, 1 neutral. The dominant filing sentiment for Alpha Tau Medical LTD. is bullish.
Filing Type Overview
Alpha Tau Medical LTD. (DRTS) has filed 2 6-K with the SEC between Mar 2026 to Apr 2026.
Recent Filings (2)
-
Alpha Tau Medical Reports Positive Clinical Trial Results
— 6-K · Apr 23, 2026 Risk: medium
Alpha Tau Medical Ltd. announced on April 23, 2026, positive results from two clinical trials. The ACAPELLA trial showed a 90% response rate in patients with un -
Alpha Tau Medical Ltd. Files 6-K Report
— 6-K · Mar 31, 2026 Risk: low
Alpha Tau Medical Ltd. filed a Form 6-K on March 31, 2026, reporting as a foreign private issuer. The filing includes a press release dated March 31, 2026, as a
Risk Profile
Risk Assessment: Of DRTS's 2 recent filings, 0 were flagged as high-risk, 1 as medium-risk, and 1 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Top Tags
clinical-trial-results (1) · oncology (1) · medical-technology (1) · 6-K (1) · regulatory-filing (1) · foreign-issuer (1)
Key Numbers
- Response Rate (CTCL): 90% — Achieved in the ACAPELLA trial for cutaneous T-cell lymphoma patients.
- Objective Response Rate (BCC): 75% — Demonstrated in the IMPACT trial for basal cell carcinoma patients.
Frequently Asked Questions
What are the latest SEC filings for Alpha Tau Medical LTD. (DRTS)?
Alpha Tau Medical LTD. has 2 recent SEC filings from Mar 2026 to Apr 2026, including 2 6-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of DRTS filings?
Across 2 filings, the sentiment breakdown is: 1 bullish, 1 neutral. The dominant sentiment is bullish.
Where can I find Alpha Tau Medical LTD. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Alpha Tau Medical LTD. (DRTS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Alpha Tau Medical LTD.?
Financial highlights for Alpha Tau Medical LTD. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for DRTS?
Investment thesis data for DRTS will be available once enriched filings are processed.
Who are the key executives at Alpha Tau Medical LTD.?
Executive information for Alpha Tau Medical LTD. is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Alpha Tau Medical LTD. stock?
Of DRTS's 2 assessed filings, 0 were flagged high-risk, 1 medium-risk, and 1 low-risk.
What are recent predictions and forward guidance from Alpha Tau Medical LTD.?
Forward guidance and predictions for Alpha Tau Medical LTD. are extracted from SEC filings as they are enriched.